Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Non-Small-Cell Lung

Explore clinical trials studying Carcinoma, Non-Small-Cell Lung. Study availability and eligibility vary by location and protocol.

4,700 public trials 1,041 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Non-Small-Cell Lung trial results

Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883

Conditions
Advanced (Inoperable) Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Bronchial Neoplasms, +9 more
Locations
  • Research Site San Diego, California, United States
  • Research Site Cleveland, Ohio, United States
  • Research Site Edegem, Belgium
  • Research Site Ghent, Belgium
View all 16 locations
View Trial Details
Completed

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

NCT01186861

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Site US10007 Jacksonville, Florida, United States
  • Site US10001 Port Saint Lucie, Florida, United States
  • Site US10002 Albany, Georgia, United States
  • Site US10008 Chicago, Illinois, United States
View all 69 locations
View Trial Details
Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • University of California, San Diego/Moores Cancer Center La Jolla, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Northwestern Memorial Hospital Chicago, Illinois, United States
View all 29 locations
View Trial Details
Completed

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

NCT05954871

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +18 more
Locations
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • START South Texas Accelerated Research Therapeutics-San Antonio San Antonio, Texas, United States
  • Border Medical Oncology Wodonga, New South Wales, Australia
  • St Vincent's Hospital Melbourne Fitzroy, Victoria, Australia
View Trial Details
Completed

TG4010 and Nivolumab in Patients With Lung Cancer

NCT02823990

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California San Diego San Diego, California, United States
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
View Trial Details
Completed

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

NCT03468426

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 43 locations
View Trial Details
Completed

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

NCT03396445

Conditions
Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +15 more
Locations
  • University of South Alabama, Mitchell Cancer Institute ( Site 0020) Mobile, Alabama, United States
  • Florida Cancer Specialists ( Site 0002) Sarasota, Florida, United States
  • The West Clinic, P.C. ( Site 0021) Germantown, Tennessee, United States
  • FALP-UIDO ( Site 0502) Santiago, Region M. de Santiago, Chile
View all 18 locations
View Trial Details

Related conditions